

Lenacapavir: Adis Evaluation

Key Points

- A long-acting HIV capsid inhibitor allowing bi-annual subcutaneous administration is being developed by Gilead Sciences Inc. for the treatment of HIV-1 infection
- Received its first approval on 22 August 2022 in the EU
- Approved in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen

Summary

Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc.

It is available as an oral tablet and injectable solution, with the latter being a slow-release formulation to allow bi-annual subcutaneous administration.

In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.